Shares of Morepen Laboratories today surged 12 per cent after the company received approval from the US health regulator for two bulk drug facilities in Himachal Pradesh.
The stock soared 11.77 per cent to settle at Rs 35.60 on the BSE. During the day, it jumped 16.48 per cent to Rs 37.10.
On the NSE, shares of the company rose sharply by 11.93 per cent to end at Rs 35.65.
In terms of equity volume, 10.79 lakh shares of the company were traded on the BSE and over 65 lakh shares changed hands on the NSE during the day.
Morepen Laboratories today said it has received approval from the US health regulator for two bulk drug facilities in Himachal Pradesh manufacturing Atorvastatin Calcium and Montelukast Sodium, respectively.
While the Baddi facility has got US Food and Drug Administration (USFDA) nod to manufacture cholesterol reducing bulk drug Atorvastatin Calcium, the Masulkhana facility has received approval for manufacturing anti-asthma bulk drug Montelukast Sodium, the company said in a BSE filing.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app